RESUMEN
Little is known of the etiology, course, and treatment of new-onset refractory status epilepticus (NORSE) in children. Here we identified etiologies, electroencephalography (EEG) characteristics, and neuroimaging findings among pediatric patients with NORSE and among two patient subgroups, febrile infection-related epilepsy syndrome (FIRES) group and non-FIRES group. We also examined treatments and risk factors related to poor prognosis. Ninety-two children with NORSE were identified in Children's Hospital of Chongqing Medical University between January 1, 2010 and September 1, 2020. The end date was chosen to guarantee at least a 6-month follow-up. Our results indicated that patients with FIRES account for 90% of pediatric patients with NORSE. The clinical, EEG, and neuroimaging results and prognosis were not significantly different between the FIRES group and non-FIRES group of individuals. 68.5% of our patients had unknown etiology, and viral etiology was the most common identified cause (26.1%). Electroencephalography might have a certain diagnostic value for NORSE. A gradual increase in seizure burden was obvious from the onset of disease, and continuous or recurrent ictal discharge lastingâ¯≥â¯30â¯min was quite common in our study. The mortality was 22.8% in our study. Among the 71 surviving patients, the outcome at discharge was poor but improved during follow-up, and 68.5% had good or fair outcomes at their last follow-up. A poor outcome was observed in 39 of 92 cases (42%), with 43.9% and 30% of individuals in the FIRES group and non-FIRES group, respectively, having a poor outcome. The presence of super refractory status epilepticus (SRSE), electrographic seizures and nonconvulsive status epilepticus (NCSE), and diffuse cortical edema and multifocal abnormality may be related to a poor prognosis. Our analysis did not indicate that prognosis was directly related to etiology or treatment. Management of NORSE is challenging, and the role of immunotherapy warrants further investigation.
Asunto(s)
Epilepsia Refractaria , Estado Epiléptico , Niño , Epilepsia Refractaria/diagnóstico , Epilepsia Refractaria/epidemiología , Electroencefalografía , Humanos , Estudios Retrospectivos , Convulsiones , Estado Epiléptico/diagnóstico , Estado Epiléptico/epidemiología , Estado Epiléptico/etiologíaRESUMEN
Major depressive disorder (MDD) in children and adolescents is a recurrent and disabling condition globally but its pathophysiology remains poorly elucidated and there are limited effective treatments available. We performed metabolic profiling of plasma samples based on ultra-high-performance liquid chromatography equipped with quadrupole time-offlight mass spectrometry to explore the potential biomarkers of depression in children and adolescents with MDD. We identified several perturbed pathways, including fatty acid metabolism-particularly the polyunsaturated fatty acids metabolism, and purine metabolism-that were associated with MDD in these young patients. In addition, inosine was shown as a potential independent diagnostic biomarker for MDD, achieving an area under the ROC curve of 0.999 in discriminating drug-naive MDD patients and 0.866 in discriminating drug-treated MDD from healthy controls. Moreover, we found evidence for differences in the pathophysiology of MDD in children and adolescents to that of adult MDD, specifically with tryptophan metabolism. Through metabolomic analysis, we have identified links between a framework of metabolic perturbations and the pathophysiology and diagnostic biomarker of child and adolescent MDD.
Asunto(s)
Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/metabolismo , Trastorno Depresivo Mayor/fisiopatología , Adolescente , Biomarcadores , Estudios de Casos y Controles , Niño , China , Cromatografía Líquida de Alta Presión , Depresión/diagnóstico , Depresión/metabolismo , Ácidos Grasos Insaturados/sangre , Ácidos Grasos Insaturados/metabolismo , Femenino , Humanos , Inosina/metabolismo , Metabolismo de los Lípidos , Masculino , Espectrometría de Masas , Metabolómica/métodos , Purinas/metabolismo , Curva ROC , Triptófano/metabolismoRESUMEN
Little is known about pediatric patients suffering from nonconvulsive status epilepticus (NCSE) after convulsive status epilepticus (CSE) cessation. The aim of this study was to identify in pediatric patients the clinical characteristics of NCSE after CSE cessation and the factors that contribute to patient outcomes. Data from clinical features, electroencephalography (EEG) characteristics, neuroimaging findings, treatments, and prognosis were systematically summarized, and the associations between clinical characteristics and prognosis were quantified. Thirty-eight children aged 51days-14years, 2months were identified in the Chongqing Medical University pediatric intensive care unit as having experienced NCSE after CSE cessation between October 1, 2014 and April 1, 2017. All patients were comatose, 15 of whom presented subtle motor signs. The most common underlying etiology was acute central nervous system (CNS) infection. Electroencephalography (EEG) data showed that, during the NCSE period, all patients had several discrete episodes (lasting from 30s to 6h long), and the most common duration was 1-5min. The ictal onset locations were classified as focal (16 patients, 42.1%), multiregional independent (10 patients, 26.3%), and generalized (12 patients, 31.6%). Wave morphologies varied during the ictal and interictal periods. Neuroimaging detected signal abnormalities in the cerebral cortex or subcortex of 33 patients with NCSE (87%), which were classified as either multifocal and consistent with extensive cortical edema (21 patients, 55.3%) or focal (12 patients, 31.6%). Twelve patients were on continuous intravenous phenobarbital, and 31 were on continuous infusion of either midazolam (27 patients) or propofol (4 patients). At least one other antiepileptic drug was prescribed for 32 patients. Three patients were on mild hypothermia therapy. The duration of NCSE lasted <24h for 20 patients and >24h for 18 patients. The mortality rate was 21.1%, and half of the surviving patients had severe neurological morbidity. Our results indicated that EEG monitoring after treatment of CSE was essential to the recognition of persistent seizures. The clinical features, EEG characteristics, and neuroimaging findings varied during the NCSE period. The morbidity is high in pediatric patients who had NCSE after CSE. Convulsive status epilepticus (CSE) duration and neuroimaging results may be related to the prognosis.
Asunto(s)
Electroencefalografía/tendencias , Unidades de Cuidado Intensivo Pediátrico/tendencias , Estado Epiléptico/diagnóstico por imagen , Estado Epiléptico/fisiopatología , Administración Intravenosa , Adolescente , Corteza Cerebral/diagnóstico por imagen , Corteza Cerebral/fisiopatología , Niño , Preescolar , Electroencefalografía/efectos de los fármacos , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Midazolam/administración & dosificación , Fenobarbital/administración & dosificación , Propofol/administración & dosificación , Estudios Retrospectivos , Estado Epiléptico/tratamiento farmacológicoRESUMEN
OBJECTIVES: The aim of our study was to retrospectively research the semiology of neonatal seizures (NSs) based on the 2021 classification scheme of the International League Against Epilepsy, and the relationship between etiology and electroclinical features. METHODS: Patients admitted to Children's Hospital of Chongqing Medical University from May 1, 2020 to March 30, 2022 and diagnosed with NSs were included to retrospectively investigate the etiology, seizure characteristics, prognosis, and ictal and interictal video electroencephalography (EEG) characteristics. RESULTS: Of the 45 patients, 73.3% had definite etiology. Twenty-seven patients had electro-clinical seizures, of which two had both electro-clinical and electrographic-only seizures. Electrographic-only seizures were reported in 18 patients. The tonic, clonic, and electrographic-only seizures were associated with various etiologies. Both tonic and clonic seizures occurred in acute symptomatic seizures and were associated with neonatal epilepsy. 50% of tonic seizures were related to genetic factors. Among the clonic seizures, 50.0% occurred in acute symptomatic seizures. Epileptic spasms always indicated neonatal epilepsy. There were few patients who experienced automatisms and sequential seizures, and these two seizure types were associated with brain malformation and genetic factors, respectively. Patients with a normal interictal EEG had acute symptomatic seizures. whereas the interictal EEG of patients with neonatal epilepsy mainly showed burst-suppression or multifocal discharges. The ictal EEG recordings were related to seizure semiology. CONCLUSION: Seizure semiology and video EEG are suggestive of potential causes but do not provide a definite etiology.
Asunto(s)
Epilepsia , Convulsiones , Niño , Recién Nacido , Humanos , Estudios Retrospectivos , Convulsiones/diagnóstico , Convulsiones/complicaciones , Epilepsia/diagnóstico , Epilepsia/complicaciones , ElectroencefalografíaRESUMEN
AIMS: To measure the effectiveness of antidepressants for adolescents and young adults with co-occurring depression and substance use disorder. DESIGN, SETTING AND PARTICIPANTS: Meta-analysis of randomized controlled clinical trials. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science and PsychINFO was conducted (from 1970 to 2013). Prospective, parallel groups, double-blind, controlled trials with random assignment to an antidepressant or placebo on young patients (age ≤ 25 years) who met diagnostic criteria of both substance use and unipolar depressive disorder were included. Five trials were selected for this analysis and included 290 patients. MEASUREMENTS: Our efficacy outcome measures were depression outcomes (dichotomous and continuous measures) and substance-use outcomes (change of frequency or quantity of substance-use). Secondary analysis was conducted to access the tolerability of antidepressant treatment. FINDINGS: For dichotomous depression outcome, antidepressants group was significantly more effective than placebo group [risk ratio (RR) = 1.21; 95% confidence interval (CI) 1.01-1.45], with low heterogeneity (I(2) = 0%). Although no statistically significant effects for continuous depression outcome [standardized mean differences (SMD) = -0.13; 95% CI, -0.55 to 0.30] were found with moderate heterogeneity (I(2) = 63%), subgroup analysis showed that the medicine group with a sample size of more than 50 showed statistically significant efficacy compared with the placebo group (SMD -0.53, 95% CI -0.82 to -0.25). Moreover, there was no significant difference for substance-use outcomes and tolerability outcomes between the medication and placebo groups. CONCLUSIONS: Antidepressant medication has a small overall effect in reducing depression in young patients with combined depressive and substance-use disorders, but does not appear to improve substance use outcomes.